News & Updates

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

14 Jul 2023 by

In the phase III ATLAS-PPX trial, the investigational siRNA* therapeutic fitusiran significantly cut bleeding events compared with factor/bypassing agent (BPA) prophylaxis in patients with haemophilia A or B with or without inhibitors.

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

14 Jul 2023

PNH carries a high disease burden despite treatment

14 Jul 2023 by

Paroxysmal nocturnal haemoglobinuria (PNH) carries a substantial disease burden and healthcare resource utilization, even in patients already receiving treatment with C5 inhibitors, according to an expert who presented at EHA 2023.

PNH carries a high disease burden despite treatment

14 Jul 2023

Tranexamic acid use before CS reduces blood loss

14 Jul 2023 by

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

Tranexamic acid use before CS reduces blood loss

14 Jul 2023

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023 by

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023 by

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023

Fremanezumab eases migraine and depressive symptoms

13 Jul 2023 by

Treatment with fremanezumab – an anticalcitonin gene-related peptide (CGRP) – reduces depressive symptoms in patients with migraine and comorbid major depressive disorder (MDD) in the UNITE trial.

Fremanezumab eases migraine and depressive symptoms

13 Jul 2023

Intravenous lacosamide for seizures well tolerated in children, infants

12 Jul 2023

Treating seizures with intravenous lacosamide appears to be safe and is associated with low rates of adverse events among critically ill children and neonates, as reported in a study.

Intravenous lacosamide for seizures well tolerated in children, infants

12 Jul 2023

Platelet-rich fibrin matrix shows promise for trophic ulcers

12 Jul 2023 by

Platelet-rich fibrin matrix (PRFM) compares favourably with platelet-rich plasma (PRP) in the treatment of chronic trophic ulcer associated with leprosy, as shown in the results of an observer-blind, noninferiority randomized controlled trial.

Platelet-rich fibrin matrix shows promise for trophic ulcers

12 Jul 2023

Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea

12 Jul 2023 by

Treatment with a microencapsulated benzoyl peroxide (E-BPO) 5% cream contributes to changes in the microbiome of the skin and results in improvements in moderate to severe rosacea, according to a study presented at the recent WCD 2023.

Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea

12 Jul 2023

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis

11 Jul 2023

Treatment with anticoagulants helps improve survival in patients with cirrhosis and portal vein thrombosis independently of recanalization, suggests a study. However, anticoagulation may increase the risk of nonportal hypertension-related bleeding.

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis

11 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

PNH carries a high disease burden despite treatment

PNH carries a high disease burden despite treatment

Tranexamic acid use before CS reduces blood loss

Tranexamic acid use before CS reduces blood loss

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Fremanezumab eases migraine and depressive symptoms

Fremanezumab eases migraine and depressive symptoms

Intravenous lacosamide for seizures well tolerated in children, infants

Intravenous lacosamide for seizures well tolerated in children, infants

Platelet-rich fibrin matrix shows promise for trophic ulcers

Platelet-rich fibrin matrix shows promise for trophic ulcers

Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea

Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis